Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CRB-601 monoclonal antibody · 1 trial · 1 indication
Incidence of treatment emergent adverse events and clinically significant changes in laboratory parameters, ECG, vital signs and physical exam findings over treatment duration
Disease Control Rate (Complete Responses plus Partial Responses plus Stable Disease for at least 4 months as determined by the Investigator using RECIST 1.1.
| Arm | Type | Description |
|---|---|---|
| Part A: Dose 1 CRB-601 monotherapy | EXPERIMENTAL | Dose 1 of CRB-601 (3mg/Kg) administered intravenously every two weeks |
| Part A: Dose 2 of CRB-601 monotherapy | EXPERIMENTAL | Dose 2 of CRB-601 (10mg/Kg) administered intravenously every two weeks |
| Part A: Dose 3 of CRB-601 monotherapy | EXPERIMENTAL | Dose 3 of CRB-601 (30mg/Kg) administered intravenously every two weeks |
| Part B/Cohort 1: Dose level (low) CRB-601 in combination with anti-PD(L)-1 | EXPERIMENTAL | Dose (defined in Part A) of CRB-601 administered intravenously in combination with anti-PD(L)-1 therapy dosed as per label. |
| Part B/Cohort 2: Dose level (high) CRB-601 in combination with anti-PD(L)-1 | EXPERIMENTAL | High dose CRB-601 (defined in Part A) of CRB-601 administered intravenously in combination with anti-PD(L)-1 therapy dosed per label. |
| Part B/Expansion: Dose level (defined in Part B/ Safety Le) CRB-601 in combination with anti-PD(L)-1 | EXPERIMENTAL | Dose (defined in Part B/ Safety Lead-In) or CRB-601 administered intravenously in combination with anti-PD(L)-1 therapy dosed per label. |
| Part C - Low dose CRB-601 in combination with anti-PD(L)-1 | EXPERIMENTAL | Participants will receive a low dose of CRB-601 (defined in Part A \&B) in combination with standard of care dose of anti-PD(L)-1 therapy. |
| Part C - High dose CRB-601 in combination with anti-PD(L)-1 | EXPERIMENTAL | Participants will receive a high dose of CRB-601 (defined in Part A \&B) in combination with standard of care dose of anti-PD(L)-1 therapy. |
| Name | Type | Description |
|---|---|---|
| CRB-601 monoclonal antibody | DRUG | CRB-601 |
| Anti-PD-1 monoclonal antibody | DRUG | Anti-PD(L)-1 used as per label |
Inclusion Criteria: * Confirmed diagnosis of select locally advanced or metastatic solid tumors that have progressed after at least one line of therapy or have no other standard therapy with proven clinical benefit available. * Measurable disease on imaging as assessed by RECIST 1.1 Eastern Coopera...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
CRB-601 monoclonal antibody is an investigational drug being developed for the treatment of solid tumors. It is currently in Phase 1 clinical development, with an ongoing first-in-human study evaluating its safety and tolerability in patients with advanced solid tumors.
CRB-601 monoclonal antibody is being developed by Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company listed on the NASDAQ under the ticker symbol CRBP. The company is conducting clinical trials for this investigational oncology asset.
CRB-601 monoclonal antibody is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study is currently recruiting participants to evaluate the drug in patients with advanced solid tumors.
CRB-601 monoclonal antibody is being studied in a Phase 1 clinical trial with the identifier NCT06603844. This first-in-human study is recruiting patients with advanced solid tumors in the United States and United Kingdom, with a planned enrollment of 156 participants.
CRB-601 monoclonal antibody is the drug being studied in the clinical trial titled 'First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.' The trial name refers to the drug as CRB-601-01, which appears to be the same investigational agent.